GARS1 and breast carcinoma: GARS1 overexpression has been associated with poorer prognosis in lung adenocarcinoma patients (8), while inhibition of GARS1 impedes the growth and colony formation of breast cancer cells (9), and depletion of GARS1 hinders cell proliferation and cell cycle progression in hepatocellular carcinoma (HCC) (10).